Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches

Abstract

Psoriasis is a chronic inflammatory skin disease with autoimmune pathological characteristics. Recent research has found a link between psoriasis, inflammation, and gut microbiota dysbiosis, and that probiotics and prebiotics provide benefits to patients. This 12-week open-label, single-center clinical trial evaluated the efficacy of probiotics (Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans (SC208), Bacillus licheniformis (SL307), and Bacillus clausii (SC109)) and precision prebiotics (fructooligosaccharides, xylooligosaccharides, and galactooligosaccharides) in patients with psoriasis receiving topical therapy, with an emphasis on potential metabolic, immunological, and gut microbiota changes. In total, 63 patients were evaluated, with the first 42 enrolled patients assigned to the intervention group and the next 21 assigned to the control group (2:1 ratio; non-randomized). There were between-group differences in several patient characteristics at baseline, including age, psoriasis severity (the incidence of severe psoriasis was greater in the intervention group than in the control group), the presence of nail psoriasis, and psoriatic arthritis, though it is not clear whether or how these differences may have affected the study findings. Patients with psoriasis receiving anti-psoriatic local therapy and probiotic and prebiotic supplementation performed better in measures of disease activity, including Psoriasis Area and Severity Index, Dermatology Life Quality Index, inflammatory markers, and skin thickness compared with those not receiving supplementation. Furthermore, in the 15/42 patients in the intervention group who received gut microbiota analysis, the gut microbiota changed favorably following 12 weeks of probiotic and prebiotic supplementation, with a shift towards an anti-inflammatory profile.

Modulation of Gut Microbiome as a Therapeutic Modality for Auditory Disorders

“…Furthermore, combination therapy consisting of probiotic administration alongside a decreased antibiotic dosage has demonstrated positive results in children [42]. In both AOM and SOM, the incorporation of probiotics such as Lactobacillus and Streptococcus strains to maintain homeostasis in the gut microbiome will help in decreasing antibiotic usage, thus reducing adverse events [50]. Much like in SNHL, studies have suggested that providing a combination therapy of probiotics with a decreased dose of antibiotics yields stronger outcomes than aggressive antibiotic treatment alone [54].…”

“…Prebiotics are micronutrients that foster the growth and activity of a beneficial gut microbiome. They are shown to be useful in diseases affecting the GI system, immune system, and nervous system in humans [46][47][48][49][50][51]. Harmful microbes which stimulate the immune system can be decreased and the cytokine environment can be modulated with prebiotics.…”

The Role of the Gut Microbiome and Microbial Dysbiosis in Common Skin Diseases

“…In addition, the gut microflora changed favourably towards an anti-inflammatory profile. The probiotics used in the study were Bacillus indicus, Bacillus subtillia, Bacillus coangulans, Bacillus licheniformjis, and Bacillus clausii, while the prebiotics given to patients were fructooligosaccharides, xyloligosaccharides, and galactooligosaccharides [108].…”

The interaction between gut microbiome and bone health

“…GM's impact extends beyond the gastrointestinal system, influencing various aspects of overall health. Understanding the GM's composition, functions, and factors is essential for unlocking its potential to maintain health and prevent diseases [ 4 ].…”